Variegate Porphyria Differential Diagnoses

1. Brenner DA, Bloomer JR. The enzymatic defect in variegate prophyria. Studies with human cultured skin fibroblasts. N Engl J Med. 1980 Apr 3. 302(14):765-9. [QxMD MEDLINE Link].

2. Meissner PN, Day RS, Moore MR, Disler PB, Harley E. Protoporphyrinogen oxidase and porphobilinogen deaminase in variegate porphyria. Eur J Clin Invest. 1986 Jun. 16(3):257-61. [QxMD MEDLINE Link].

3. Kirsch RE, Meissner PN, Hift RJ. Variegate porphyria. Semin Liver Dis. 1998. 18(1):33-41. [QxMD MEDLINE Link].

4. Whatley SD, Puy H, Morgan RR, et al. Variegate porphyria in Western Europe: identification of PPOX gene mutations in 104 families, extent of allelic heterogeneity, and absence of correlation between phenotype and type of mutation. Am J Hum Genet. 1999 Oct. 65(4):984-94. [QxMD MEDLINE Link].

5. Eales L, Day RS, Blekkenhorst GH. The clinical and biochemical features of variegate porphyria: an analysis of 300 cases studied at Groote Schuur Hospital, Cape Town. Int J Biochem. 1980. 12(5-6):837-53. [QxMD MEDLINE Link].

6. Mustajoki P. Variegate porphyria. Twelve years' experience in Finland. Q J Med. 1980 Spring. 49(194):191-203. [QxMD MEDLINE Link].

7. Bonkowsky HL, Schady W. Neurologic manifestations of acute porphyria. Semin Liver Dis. 1982 May. 2(2):108-24. [QxMD MEDLINE Link].

8. Bonkovsky HL, Barnard GF. The Porphyrias. Curr Treat Options Gastroenterol. 2000 Dec. 3(6):487-500. [QxMD MEDLINE Link].

9. Meissner P, Adams P, Kirsch R. Allosteric inhibition of human lymphoblast and purified porphobilinogen deaminase by protoporphyrinogen and coproporphyrinogen. A possible mechanism for the acute attack of variegate porphyria. J Clin Invest. 1993 Apr. 91(4):1436-44. [QxMD MEDLINE Link].

10. Meyer UA, Schuurmans MM, Lindberg RL. Acute porphyrias: pathogenesis of neurological manifestations. Semin Liver Dis. 1998. 18(1):43-52. [QxMD MEDLINE Link].

11. Yasuda M, Chen B, Desnick RJ. Recent advances on porphyria genetics: Inheritance, penetrance & molecular heterogeneity, including new modifying/causative genes. Mol Genet Metab. 2018 Nov 30. [QxMD MEDLINE Link].

12. Susa S, Sato-Monma F, Ishii K, Hada Y, Takase K, Tada K, et al. Transient Worsening of Photosensitivity due to Cholelithiasis in a Variegate Porphyria Patient. Intern Med. 2016. 55 (20):2965-2969. [QxMD MEDLINE Link].

13. Corrigall AV, Hift RJ, Davids LM, et al. Homozygous variegate porphyria in South Africa: genotypic analysis in two cases. Mol Genet Metab. 2000 Apr. 69(4):323-30. [QxMD MEDLINE Link].

14. Hift RJ, Meissner PN, Todd G, et al. Homozygous variegate porphyria: an evolving clinical syndrome. Postgrad Med J. 1993 Oct. 69(816):781-6. [QxMD MEDLINE Link].

15. Meissner PN, Dailey TA, Hift RJ, Ziman M, Corrigall AV, Roberts AG. A R59W mutation in human protoporphyrinogen oxidase results in decreased enzyme activity and is prevalent in South Africans with variegate porphyria. Nat Genet. 1996 May. 13(1):95-7. [QxMD MEDLINE Link].

16. Dean G. The porphyrias. A story of inheritance and environment. London: Pitman Medical; 1971. 2nd ed.

17. van Serooskerken AM, Ernst M, Bladergroen RS, Wolff C, Floderus Y, Harper P. A recurrent mutation in variegate porphyria patients from Chile and Sweden: Evidence for a common genetic background?. J Dermatol Sci. 2011 Jan. 61(1):75-7. [QxMD MEDLINE Link].

18. Frank J, Alta VM, Ahmad W, Lam H, Wolff C, Christiano AM. Identification of a Founder Mutation in the Protoporphyrinogen Oxidase Gene in Variegate Porphyria Patients from Chile. Human Heredity. 2001. 51:160-8.

19. Granata BX, Parera VE, Batlle A, Rossetti MV. Haplotype Study in Argentinean Variegate Porphyria Patients. Hum Hered. 2015. 80 (3):139-43. [QxMD MEDLINE Link].

20. Elder G, Harper P, Badminton M, Sandberg S, Deybach JC. The incidence of inherited porphyrias in Europe. J Inherit Metab Dis. 2012 Nov 1. [QxMD MEDLINE Link].

21. Edel Y, Mamet R, Snast I, Kaftory R, Mazor S, Hodak E, et al. Epidemiology of cutaneous porphyria in Israel: a nationwide cohort study. J Eur Acad Dermatol Venereol. 2019 Jul 2. [QxMD MEDLINE Link].

22. Ramanujam VS, Anderson KE. Porphyria Diagnostics-Part 1: A Brief Overview of the Porphyrias. Curr Protoc Hum Genet. 2015 Jul 1. 86:17.20.1-17.20.26. [QxMD MEDLINE Link].

23. Mustajoki P, Tenhunen R, Niemi KM, Nordmann Y, Kaariainen H, Norio R. Homozygous variegate porphyria. A severe skin disease of infancy. Clin Genet. 1987 Nov. 32(5):300-5. [QxMD MEDLINE Link].

24. Hift RJ, Meissner PN. An analysis of 112 acute porphyric attacks in Cape Town, South Africa: Evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity. Medicine (Baltimore). 2005 Jan. 84(1):48-60. [QxMD MEDLINE Link].

25. von und zu Fraunberg M, Timonen K, Mustajoki P, Kauppinen R. Clinical and biochemical characteristics and genotype-phenotype correlation in Finnish variegate porphyria patients. Eur J Hum Genet. 2002 Oct. 10(10):649-57. [QxMD MEDLINE Link].

26. Hift RJ, Meissner D, Meissner PN. A systematic study of the clinical and biochemical expression of variegate porphyria in a large South African family. Br J Dermatol. 2004 Aug. 151(2):465-71. [QxMD MEDLINE Link].

27. Korda V, Deybach JC, Martasek P, et al. Homozygous variegate porphyria. Lancet. 1984 Apr 14. 1(8381):851. [QxMD MEDLINE Link].

28. Dawit S, Bhatt SK, Das DM, Pines AR, Shiue HJ, Goodman BP, et al. Nonconvulsive status epilepticus secondary to acute porphyria crisis. Epilepsy Behav Case Rep. 2019. 11:43-46. [QxMD MEDLINE Link].

29. Rasheed F, Mehdi QS, Bhatti S, Ali Khan MM. Posterior Reversible Encephalopathy Syndrome in a Patient with Variegate Porphyria: A Case Report. Cureus. 2018 Sep 24. 10 (9):e3351. [QxMD MEDLINE Link].

30. Church SE, McColl KE, Moore MR, Youngs GR. Hypertension and renal impairment as complications of acute porphyria. Nephrol Dial Transplant. 1992. 7 (10):986-90. [QxMD MEDLINE Link].

31. Schneider-Yin X, van Tuyll van Serooskerken AM, Went P, Tyblewski W, Poblete-Gutiérrez P, Minder EI. Hepatocellular carcinoma in variegate porphyria: a serious complication. Acta Derm Venereol. 2010 Sep. 90(5):512-5. [QxMD MEDLINE Link].

32. Luvai A, Mbagaya W, Narayanan D, Degg T, Toogood G, Wyatt JI, et al. Hepatocellular carcinoma in variegate porphyria: a case report and literature review. Ann Clin Biochem. 2015 May. 52 (Pt 3):407-12. [QxMD MEDLINE Link].

33. Singal AK, Anderson KE. Variegate porphyria. GeneReviews - NCBI Bookshelf. Feb 14, 2013. [QxMD MEDLINE Link]. [Full Text].

34. Peoc'h K, Manceau H, Karim Z, Wahlin S, Gouya L, Puy H, et al. Hepatocellular carcinoma in acute hepatic porphyrias: A Damocles Sword. Mol Genet Metab. 2018 Oct 9. [QxMD MEDLINE Link].

35. Herrick AL, Moore MR, Thompson GG, Ford GP, McColl KE. Cholelithiasis in patients with variegate porphyria. J Hepatol. 1991 Jan. 12 (1):50-3. [QxMD MEDLINE Link].

36. Muraldihar A, Vikram RS, Pechtor K, Howell MR. Recurrent variegate porphyria in a pregnant woman. Journal of Obstetrics and Gynaecology. 2006. 8:809-824.

37. Wolff C, Merino RA. Porfiria y embarazo. Rev Med Chile. 2008. 136:151-156.

38. Marsden JT, Rees DC. A retrospective analysis of outcome of pregnancy in patients with acute porphyria. J Inherit Metab Dis. 2010 Oct. 33(5):591-6. [QxMD MEDLINE Link].

39. Badminton MN, Deybach JC. Treatment of an acute attack of porphyria during pregnancy. Eur J Neurol. 2006 Jun. 13 (6):668-9. [QxMD MEDLINE Link].

40. Sassa S. Modern diagnosis and management of the porphyrias. Br J Haematol. 2006 Nov. 135(3):281-92. [QxMD MEDLINE Link].

41. Zaider E, Bickers DR. Clinical laboratory methods for diagnosis of the porphyrias. Clin Dermatol. 1998 Mar-Apr. 16(2):277-93. [QxMD MEDLINE Link].

42. Hift RJ, Davidson BP, van der Hooft C, Meissner DM, Meissner PN. Plasma fluorescence scanning and fecal porphyrin analysis for the diagnosis of variegate porphyria: precise determination of sensitivity and specificity with detection of protoporphyrinogen oxidase mutations as a reference standard. Clin Chem. 2004 May. 50(5):915-23. [QxMD MEDLINE Link].

43. Kühnel A, Gross U, Jacob K, Doss MO. Studies on coproporphyrin isomers in urine and feces in the porphyrias. Clin Chim Acta. 1999 Apr. 282 (1-2):45-58. [QxMD MEDLINE Link].

44. Poh-Fitzpatrick MB. A plasma porphyrin fluorescence marker for variegate porphyria. Arch Dermatol. 1980 May. 116(5):543-7. [QxMD MEDLINE Link].

45. Logan GM, Weimer MK, Ellefson M, Pierach CA, Bloomer JR. Bile porphyrin analysis in the evaluation of variegate porphyria. N Engl J Med. 1991 May 16. 324(20):1408-11. [QxMD MEDLINE Link].

46. Wang B, Rudnick S, Cengia B, Bonkovsky HL. Acute Hepatic Porphyrias: Review and Recent Progress. Hepatol Commun. 2019 Feb. 3 (2):193-206. [QxMD MEDLINE Link].

47. Loskove Y, Yasuda M, Chen B, Nazarenko I, Cody N, Desnick RJ. Acute hepatic porphyrias: Identification of 46 hydroxymethylbilane synthase, 11 coproporphyrinogen oxidase, and 20 protoporphyrinogen oxidase novel mutations. Mol Genet Metab. 2018 Oct 26. [QxMD MEDLINE Link].

48. Chen B, Whatley S, Badminton M, et al. International Porphyria Molecular Diagnostic Collaborative: an evidence-based database of verified pathogenic and benign variants for the porphyrias. Genet Med. 2019 Nov. 21 (11):2605-2613. [QxMD MEDLINE Link].

49. Epstein JH, Tuffanelli DL, Epstein WL. Cutaneous changes in the porphyrias. A microscopic study. Arch Dermatol. 1973 May. 107(5):689-98. [QxMD MEDLINE Link].

50. Timonen K, Niemi KM, Mustajoki P, Tenhunen R. Skin changes in variegate porphyria. Clinical, histopathological, and ultrastructural study. Arch Dermatol Res. 1990. 282(2):108-14. [QxMD MEDLINE Link].

51. Anderson KE, Bloomer JR, Bonkovsky HL, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med. 2005 Mar 15. 142(6):439-50. [QxMD MEDLINE Link].

52. Kalman DR, Bonkovsky HL. Management of acute attacks in the porphyrias. Clin Dermatol. 1998 Mar-Apr. 16(2):299-306. [QxMD MEDLINE Link].

53. Findley H, Philips A, Cole D, Nair A. Porphyrias: implications for anaesthesia, critical care, and pain medicine. Oxford Journals. Available at http://ceaccp.oxfordjournals.org/content/early/2012/02/27/bjaceaccp.mks009.full. February 27, 2012; Accessed: April 8, 2016.

54. Pischik E, Kauppinen R. An update of clinical management of acute intermittent porphyria. Appl Clin Genet. 2015. 8:201-14. [QxMD MEDLINE Link].

55. Tschudy DP, Welland FH, Collins A, Hunter G Jr. The effect of carbohydrate feeding on the induction of delta-aminolevulinic acid synthatase. Metabolism. 1964 May. 13:396-406. [QxMD MEDLINE Link].

56. Bonkovsky HL, Healey JF, Lourie AN, Gerron GG. Intravenous heme-albumin in acute intermittent porphyria: evidence for repletion of hepatic hemoproteins and regulatory heme pools. Am J Gastroenterol. 1991 Aug. 86(8):1050-6. [QxMD MEDLINE Link].

57. Yasuda M, Gan L, Chen B, Kadirvel S, Yu C, Phillips JD, et al. RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice. Proc Natl Acad Sci U S A. 2014 May 27. 111 (21):7777-82. [QxMD MEDLINE Link].

58. Anderson KE, Spitz IM, Sassa S, Bardin CW, Kappas A. Prevention of cyclical attacks of acute intermittent porphyria with a long-acting agonist of luteinizing hormone-releasing hormone. N Engl J Med. 1984 Sep 6. 311(10):643-5. [QxMD MEDLINE Link].

59. Sardh E, Harper P, Balwani M, Stein P, Rees D, Bissell DM, et al. Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria. N Engl J Med. 2019 Feb 7. 380 (6):549-558. [QxMD MEDLINE Link].

60. Stojeba N, Meyer C, Jeanpierre C, et al. Recovery from a variegate porphyria by a liver transplantation. Liver Transpl. 2004 Jul. 10(7):935-8. [QxMD MEDLINE Link].

Carol E Cheng, MD Assistant Clinical Professor of Dermatology, University of California, Los Angeles, David Geffen School of Medicine

Disclosure: Nothing to disclose.

Michael Lor MD Candidate, University of California, Los Angeles, David Geffen School of Medicine

Disclosure: Nothing to disclose.

Richard P Vinson, MD Assistant Clinical Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Texas Medical Association, Association of Military Dermatologists, Texas Dermatological Society

Disclosure: Nothing to disclose.

Julia R Nunley, MD Professor, Department of Dermatology, Virginia Commonwealth University Medical Center

Julia R Nunley, MD is a member of the following medical societies: American Academy of Dermatology, American College of Physicians, American Society of Nephrology, International Society of Nephrology, Medical Dermatology Society, Medical Society of Virginia, National Kidney Foundation, Phi Beta Kappa, Women's Dermatologic Society

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: American Board of Dermatology<br/>Author for: Up-to-date.

Dirk M Elston, MD Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

David Timothy Woodley, MD Professor and Chair, Department of Dermatology, Keck School of Medicine of the University of Southern California

David Timothy Woodley, MD is a member of the following medical societies: American Academy of Dermatology, American Association for the Advancement of Science, American College of Emergency Physicians, American College of Physicians, American Federation for Medical Research, American Society for Clinical Investigation, New York Academy of Medicine, Society for Investigative Dermatology, Southern Medical Association

Disclosure: Received consulting fee from Shire Pharmaceuticals for consulting.

Maureen B Poh-Fitzpatrick, MD Professor Emerita of Dermatology and Special Lecturer, Columbia University College of Physicians and Surgeons

Maureen B Poh-Fitzpatrick, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, New York Academy of Medicine, New York Dermatological Society

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article